Lifestyle Modification: Evaluation of the Effects of Physical Activity and Low-Glycemic-Index Mediterranean Diet on Fibrosis Score.
Mediterranean diet
chronic liver disease
lifestyle
liver fibrosis
non-alcoholic fatty liver disease
physical activity
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
10 Aug 2023
10 Aug 2023
Historique:
received:
18
07
2023
revised:
03
08
2023
accepted:
08
08
2023
medline:
28
8
2023
pubmed:
26
8
2023
entrez:
26
8
2023
Statut:
epublish
Résumé
Non-Alcoholic Fatty Liver Disease (NAFLD) is one the most prevalent causes of chronic liver disease worldwide. In the absence of an approved drug treatment, lifestyle modification is the first intervention strategy. This study aimed to estimate the main effect of two different physical activity (PA) programs, and a Low-Glycemic-Index Mediterranean Diet (LGIMD), or their combined effect on liver fibrosis parameters in subjects with NAFLD. Subjects with moderate or severe NAFLD grade of severity (n = 144) were randomly assigned to six intervention arms for three months: LGIMD, PA programs, and their combination. Data were collected at baseline, 45 days, and 90 days. Transient elastography was performed to assess the outcome. at 90 days, a statistically significant reduction in kPa was found among subjects following LGMID (-2.85, 95% CI -5.24, -0.45) and those following an LGIMD plus PA1 (-2.37, 95% CI -4.39, -0.35) and LGIMD plus Pa2 (-2.21, 95% CI -4.10, -0.32). The contrast between time 2 and time 1 of the LGIMD plus PA2 treatment showed a statistically significant increase, and vice versa: the contrast between time 3 and time 2 of the same treatment showed a statistically significant reduction. The PA1 and PA2 arms also showed reduced kPa, although the results did not reach statistical significance. The intervention arms, LGIMD, LGIMD+PA1, and LGIMD+PA2, reduced the fibrosis score.
Sections du résumé
BACKGROUND
BACKGROUND
Non-Alcoholic Fatty Liver Disease (NAFLD) is one the most prevalent causes of chronic liver disease worldwide. In the absence of an approved drug treatment, lifestyle modification is the first intervention strategy. This study aimed to estimate the main effect of two different physical activity (PA) programs, and a Low-Glycemic-Index Mediterranean Diet (LGIMD), or their combined effect on liver fibrosis parameters in subjects with NAFLD.
METHODS
METHODS
Subjects with moderate or severe NAFLD grade of severity (n = 144) were randomly assigned to six intervention arms for three months: LGIMD, PA programs, and their combination. Data were collected at baseline, 45 days, and 90 days. Transient elastography was performed to assess the outcome.
RESULTS
RESULTS
at 90 days, a statistically significant reduction in kPa was found among subjects following LGMID (-2.85, 95% CI -5.24, -0.45) and those following an LGIMD plus PA1 (-2.37, 95% CI -4.39, -0.35) and LGIMD plus Pa2 (-2.21, 95% CI -4.10, -0.32). The contrast between time 2 and time 1 of the LGIMD plus PA2 treatment showed a statistically significant increase, and vice versa: the contrast between time 3 and time 2 of the same treatment showed a statistically significant reduction. The PA1 and PA2 arms also showed reduced kPa, although the results did not reach statistical significance.
CONCLUSIONS
CONCLUSIONS
The intervention arms, LGIMD, LGIMD+PA1, and LGIMD+PA2, reduced the fibrosis score.
Identifiants
pubmed: 37630711
pii: nu15163520
doi: 10.3390/nu15163520
pmc: PMC10459797
pii:
doi:
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Regione Puglia
ID : RC 2012-2014, Linea 4, C 32 (D.D.n.110/2014) and by Apulia Region D.G.R. n. 1159, 28 June 2018 and 2019
Références
Int J Obes Relat Metab Disord. 1992 Apr;16(4):263-8
pubmed: 1318280
Public Health Nutr. 2004 Oct;7(7):937-41
pubmed: 15482621
Amino Acids. 2012 Apr;42(4):1151-61
pubmed: 20957395
JGH Open. 2020 May 05;4(5):808-817
pubmed: 33102749
Hepatology. 2009 Oct;50(4):1072-8
pubmed: 19585618
Diabet Med. 2007 Jan;24(1):1-6
pubmed: 17227317
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
Rev Fac Cien Med Univ Nac Cordoba. 2019 Feb 27;76(1):26-36
pubmed: 30882339
Public Health Nutr. 2002 Dec;5(6B):1113-24
pubmed: 12639222
Sci Rep. 2017 Feb 22;7:43029
pubmed: 28223710
Hepatology. 2008 Aug;48(2):449-57
pubmed: 18627003
J Am Coll Cardiol. 2001 Jan;37(1):153-6
pubmed: 11153730
J Hepatol. 2017 Jan;66(1):142-152
pubmed: 27639843
Expert Rev Gastroenterol Hepatol. 2019 Jun;13(6):523-530
pubmed: 31018719
Rev Recent Clin Trials. 2014;9(3):170-7
pubmed: 25514917
Metab Syndr Relat Disord. 2014 Jun;12(5):290-8
pubmed: 24689911
World J Gastroenterol. 2020 Oct 21;26(39):5919-5943
pubmed: 33132645
Clin Gastroenterol Hepatol. 2022 Jun;20(6):e1438-e1455
pubmed: 34214678
Nutrients. 2020 Dec 28;13(1):
pubmed: 33379253
Int J Environ Res Public Health. 2021 Aug 25;18(17):
pubmed: 34501508
J Investig Med. 2012 Dec;60(8):1147-50
pubmed: 23072903
Gastroenterology. 2015 Aug;149(2):278-81
pubmed: 26116800
J Nutr Health Aging. 2017;21(4):404-412
pubmed: 28346567
Gastroenterology. 2015 Aug;149(2):367-78.e5; quiz e14-5
pubmed: 25865049
Nutrients. 2018 Sep 13;10(9):
pubmed: 30217048
Am J Clin Nutr. 2009 Dec;90(6):1656-64
pubmed: 19828712
Ultrasound Med Biol. 2016 Jan;42(1):104-9
pubmed: 26385053
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
Adv Nutr. 2015 Jul 15;6(4):461-73
pubmed: 26178030
Clin Transl Gastroenterol. 2021 Mar;12(3):e00316
pubmed: 33939383
Clin Gastroenterol Hepatol. 2020 Mar;18(3):744-746.e1
pubmed: 31100460
Res Q Exerc Sport. 1992 Jun;63(2):191-5
pubmed: 1585066
Clin Gastroenterol Hepatol. 2019 Feb;17(3):543-550.e2
pubmed: 30012432
Biochem Biophys Res Commun. 2013 Nov 1;440(4):774-9
pubmed: 24120495
J Hepatol. 2017 Oct;67(4):829-846
pubmed: 28545937
Hepatology. 2009 Oct;50(4):1105-12
pubmed: 19637289
PLoS One. 2017 Mar 27;12(3):e0173499
pubmed: 28346543
Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6474-9
pubmed: 9177242
Crit Rev Food Sci Nutr. 2009 Feb;49(2):145-52
pubmed: 18989833
Am J Gastroenterol. 2011 Mar;106(3):460-8; quiz 469
pubmed: 21206486
Nutrients. 2023 May 10;15(10):
pubmed: 37242135
Clin Gastroenterol Hepatol. 2017 Jan;15(1):96-102.e3
pubmed: 27521509
Front Nutr. 2023 Feb 22;10:1062008
pubmed: 36908910
J Appl Physiol (1985). 2012 Jul;113(1):1-6
pubmed: 22582214
Gut. 2011 Sep;60(9):1278-83
pubmed: 21708823
Nat Med. 2012 Jul 06;18(7):1028-40
pubmed: 22772564
Endocr Pract. 2022 May;28(5):528-562
pubmed: 35569886